Jaguar health announces initial close in private placement financing round for napo therapeutics s.p.a.

This closing on funds from sprim global investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million jaguar currently owns approximately 73.5% of napo therapeutics napo therapeutics' mission is to provide access to jaguar's proprietary first-in-class plant-based medicine crofelemer in europe to address significant rare disease indications san francisco, ca / accesswire / february 9, 2023 / jaguar health, inc. (nasdaq:jagx) today announced a closing in a private placement financing round for napo therapeutics, the italian corporation established by jaguar in milan, italy in 2021 that focuses on expanding crofelemer access in europe. "as majority shareholders of napo therapeutics, we are very pleased with the closing of this initial investment which is part of a larger round of napo therapeutics funding expected to close before march 31, 2023.
JAGX Ratings Summary
JAGX Quant Ranking